Kamada Secures $25M Latin America Supply Deal
Ticker: KMDA · Form: 6-K · Filed: Jan 22, 2025 · CIK: 1567529
| Field | Detail |
|---|---|
| Company | Kamada Ltd (KMDA) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $25 Million |
| Sentiment | bullish |
Sentiment: bullish
Topics: contract, supply-agreement, international-expansion, pharmaceuticals
TL;DR
Kamada inks $25M, 3-year deal for KAMRAB/VARIZIG in Latin America.
AI Summary
Kamada Ltd. announced on January 22, 2025, a new 3-year contract worth $25 million for the supply of its KAMRAB® and VARIZIG® products in Latin America. This agreement is incorporated by reference into several of Kamada's Form S-8 Registration Statements.
Why It Matters
This contract signifies a significant expansion of Kamada's market reach in Latin America, potentially boosting revenue and solidifying its presence in the region.
Risk Assessment
Risk Level: medium — The risk level is medium due to the reliance on a single contract for a specific region and product line, which could be subject to market fluctuations or regulatory changes.
Key Numbers
- $25M — Contract Value (Total revenue expected from the 3-year supply agreement in Latin America.)
- 3-Year — Contract Duration (Length of the agreement for supplying KAMRAB® and VARIZIG®.)
Key Players & Entities
- Kamada Ltd. (company) — Registrant and party to the contract
- $25 Million (dollar_amount) — Value of the new contract
- 3-Year (date) — Duration of the contract
- KAMRAB® (product) — Product to be supplied under the contract
- VARIZIG® (product) — Product to be supplied under the contract
- Latin America (location) — Region for product supply
FAQ
What specific products are included in the $25 million contract?
The contract is for the supply of KAMRAB® and VARIZIG®.
What is the duration of this new contract?
The contract is for a period of 3 years.
In which geographical region will Kamada supply these products?
The supply will be for Latin America.
What is the total value of the contract announced?
The contract is valued at $25 million.
How is this Form 6-K related to Kamada's S-8 Registration Statements?
This Form 6-K is being incorporated by reference into Kamada's Form S-8 Registration Statements, including File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, and 333-265866.
Filing Stats: 217 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2025-01-22 07:00:02
Key Financial Figures
- $25 Million — is attached: 99.1 Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB&re
Filing Documents
- ea0228245-6k_kamada.htm (6-K) — 11KB
- ea022824501ex99-1_kamada.htm (EX-99.1) — 17KB
- 0001213900-25-005187.txt ( ) — 29KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of January 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720 , 333-207933 , 333-215983 , 333-222891 , 333-233267 and 333-265866 . The following exhibit is attached: 99.1 Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 22, 2025 KAMADA LTD. By: /s/ Nir Livneh Nir Livneh Vice President General Counsel and Corporate Secretary 2 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America 3